The Samuel Waxman Cancer Research Foundation (SWCRF), founded in 1975, is a non-profit organization dedicated to conducting basic, translational, and clinical research with the goal of developing effective targeted treatments for cancer. SWCRF funds research in leading institutions in the United States, Canada, China, and Israel; fosters collaborations; trains scientists; and organizes international conferences to develop novel approaches to prevent and treat cancer. SWCRF develops research programs in the form of an “Institution Without Walls” that spans institutions and disciplines and seeks to identify investigators who are best able to attack specific problems related to cancer. To date, the SWCRF has awarded approximately $100 million to more than 200 investigators.

The Samuel Waxman Cancer Research Foundation is pleased to announce a Request for Applications (RFA) for 8 (eight) new two-year awards of $100,000/year. The Foundation anticipates funding half of the awards for research that will focus on the interplay of aging and cancer; the other half for research that will address aspects of aberrant gene expression, differentiation, or epigenetic therapies that relate to cancer. Directors of major aging and cancer research programs are invited to submit one application per institution.

**Potential themes related to aging and cancer include:**
- Aging-associated changes in stem cell function related to cancer
- Mechanisms of age-associated clonal evolution in somatic tissues
- Chromatin/epigenetic mechanisms in aging and cancer
- Mutation and/or de-repression of non-coding genome in aging and cancer
- Aging-associated DNA damage response pathways and genomic instability in cancer
- Aging-associated changes in metabolism related to cancer
- Decline in tissue maintenance in old age as a potential link to cancer incidence
- Contributions of the microenvironment in aging-associated tumor formation
- Inter-organ system communication in aging and cancer
- Human premature aging disorders as model systems of aging-associated cancer
- Novel mouse models to study the role of aging in cancer

Based on its long-standing interest in differentiation therapy for cancer, the SWCRF will continue to solicit applications related to:
- Transcription-based approaches to cancer
- Novel therapies/pathways to overcome defective differentiation of cancer cells
- Targeting aberrant signaling pathways characteristic of the malignant phenotype
- Selective apoptotic agents and pathways in cancer
Recipients of the SWCRF cancer research awards are encouraged to develop collaborations with other SWCRF investigators to continue scientific interactions beyond the term of their grant and form a society of investigators committed to:

**COLLABORATION:**
- Formulation of research plans to augment other SWCRF research programs
- Sharing of research materials, reagents, and/or core resources
- Joint publications
- Development of NIH program project grants (P01s) and/or collaborative R01s

**LETTER OF INTENT:**
Letters of Intent should be submitted using the attached document and are due March 22, 2019 via email to winshipgrants@emory.edu. Letters of Intent should also include the PI’s NIH Biosketch, a proposed title for the research project, and a brief 1-2 page abstract of the proposed research project. The selected investigator will be notified and invited to submit a full application by Winship.

**IMPORTANT DATES:**
- **Winship Letter of intent Due Date:** by Friday, March 22, 2019.
- **Winship Announcement of Nominee Selection:** by Monday, April 1, 2019.
- **Samuel Waxman Cancer Research Foundation LOI Due Date:** Monday, April 1, 2019.
- **Samuel Waxman Cancer Research Foundation Invitations for Full Application:** Monday, April 22, 2019.
- **Samuel Waxman Cancer Research Foundation Due Date:** by Saturday, June 1, 2019.
- **Samuel Waxman Cancer Research Foundation Funding Decision:** Monday July 1, 2019.